The application of γ interferon release test in detecting the latent infection of Mycobacterium tuberculosis

Abstract

XIONG Yong-chao, HOU Yue-yun, ZHAO Jian-zhong, GUO Hui, HE Guang-xue. The application of γ interferon release test in detecting the latent infection of Mycobacterium tuberculosis[J]. Chinese Journal of Antituberculosis, 2012, 34(9): 613-616.

References

［1］Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Golbal Surveillance and Monitoring Project. JAMA，1999,287:677-686.

［2］全国结核病流行病学抽样调查技术指导组，全国结核病流行病学抽样调查办公室.2000年全国结核病流行病学抽样调查报告.中国防痨杂志,2002,24(2):65-108.

［3］王宇.全国第五次结核病流行病学抽样调查资料汇编.北京:军事医学科学出版社,2011:1-6.

［4］Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med， 2006,173(8):927-931.

［5］谢莉,马屿,高微微,等. 抗原刺激后外周血单个核细胞γ干扰素释放反应在结核分枝杆菌感染和结核病诊断中的意义.中华结核和呼吸杂志,2005,28(8):545-549.

［6］Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J, 2011,37(1):88-89.

［7］Food and Drug Administration. QuantiFERON-TB-P010033［EB/OL］.［2012-06-20］. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm084025.htm.

［8］Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep，2005,54(RR-15):49-55.

［9］Food and Drug Administration. QuantiFERON-TB Gold In-Tube-P010033/S011［EB/OL］. ［2012-06-20］. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/Device-ApprovalsandClearances/PMAApprovals/ucm106548.htm.

［10］Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med，2008,149（3）:177-184.

［11］Higuchi K, Kawabe Y, Mitarai S, et al. Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol，2009,198(1): 33-37.

［12］Kampmann B, Whittaker E, Williams A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J, 2009,33(6): 1374-1382.

［13］Legesse M, Ameni G, Mamo G, et al. Performance of QuantiFERON-TB Gold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia. BMC Infect Dis, 2010,10:354.

［14］Soysal A, Torun T, Efe S, et al. Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M.tuberculosis infection. Int J Tuberc Lung Dis, 2008, 12（1）:50-56.

［15］Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection:an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med, 2004,170(1):59-64.

［16］Lee JY, Choi HJ, Park IN, et al.Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J, 2006,28（1）:24-30.

［17］Kanunfre KA, Leite OH, Lopes MI, et al. Enhancement of diagnostic efficiency by a gamma interferon release assay for pulmonary tuberculosis. Clin Vaccine Immunol, 2008, 15（6）:1028-1030.

［18］Nienhaus A, Schablon A, Costa JT, et al. Systematic review of cost and costeffectiveness of different TB-screening strategies. BMC Health Serv Res, 2011,11(1): 247.

［19］Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J，2006, 28（1）:35-44.

［20］陈群飞,王莉,李幼平，等.γ-干扰素释放试验筛查潜伏性结核患者的成本效果分析.中国循证医学杂志，2011,11(7):768-774.

［21］Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis,2007,11(1):16-26.

［22］Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-γ release assay screening for latent tuberculosis infection treatment in Germany. Chest，2007,131(5): 1424-1434.

［23］The 81st annual meeting of the Japanese Society for Tuberculosis. Sendai, Japan. April 2628, 2006. Program and Abstracts. Kekkaku,2006,81(3):105-319.

［24］时春虎，康振，杨克虎,等.γ-干扰素释放试验诊断儿童潜伏结核菌感染的Meta分析.中国循证儿科杂志,2010,7(4):263-270.

［25］Newton SM， Brent AJ， Anderson S， et al． Paediatric tuberculosis． Lancet Infect Dis， 2008，8(8):498-510．

［26］孙琳,焦伟伟,赵顺英,等. ELISPOT 检测技术在儿童结核病诊断中的应用.标记免疫分析与临床,2008,15(6):349-353.

［27］Ariga H, Harada N. Evolution of IGRA researches.Kekkaku,2008,83(9):641-652.

［28］Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med，2007,20(6):540-547.

［29］Moreno S, Blázquez R, Novoa A, et al. The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees. Arch Intern Med，2001,161(14):1760-1765.

［30］Jones S, de Gijsel D, Wallach FR, et al. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis，2007,11(11):1190-1195.

［31］康振,时春虎,田金徽,等. γ干扰素释放试验诊断艾滋病患者潜伏结核感染的Meta分析.循证医学,2010,10(6):359-363.

［32］Hoffmann M, Tsinalis D, Vernazza P, et al. Assessment of an interferon-gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly， 2010,140(19/20): 286-292.